Eculizumab in Myasthenia Gravis: A Multicenter Retrospective Real-World Study in China
Yue Li, Huan Yang, Song Tan, Lijun Luo, Xuebing Cao, JinQuan Hu, Bitao Bu, Ting Chang, Zhijun Li · 2026
Read Eculizumab in Myasthenia Gravis: A Multicenter Retrospective Real-World Study in China by Yue Li, Huan Yang, Song Tan, Lijun Luo, Xuebing Cao, JinQuan Hu, Bitao Bu, Ting Chang, Zhijun Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13396110.txt.
Description
Yue Li and colleagues gathered records from six medical centers in China on 60 people with myasthenia gravis treated with eculizumab, a drug that blocks part of the immune system. Their 2026 real-world study fills a gap, since most proof for the drug comes from tightly run trials.
Charts yielded daily-living scores, strength scores, and steroid doses at the start, at weeks one, four, and eight, and at final follow-up. By week eight, about 31 percent had reached minimal symptoms or better, rising to about 33 percent at last check. Daily-living scores fell, and the authors also report steroid use and side effects over the course.
Catalog record
| CREATOR | Yue Li, Huan Yang, Song Tan, Lijun Luo, Xuebing Cao, JinQuan Hu, Bitao Bu, Ting Chang, Zhijun Li |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51168 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |